Results 321 to 330 of about 183,644 (348)

Chimeric antigen receptor T‐cell therapy in multiple myeloma: A comprehensive review of current data and implications for clinical practice

Ca-A Cancer Journal for Clinicians, 2023

exaly  

Interleukin-6 Induces Oxidative Stress and Endothelial Dysfunction by Overexpression of the Angiotensin II Type 1 Receptor

Circulation Research, 2004
S. Wassmann, M. Stumpf, K. Strehlow, A. Schmid, B. Schieffer, M. Böhm, G. Nickenig   +6 more
semanticscholar   +1 more source

Critical care management of chimeric antigen receptor T‐cell therapy recipients

Ca-A Cancer Journal for Clinicians, 2022
Alexander Shimabukuro-Vornhagen, Boris Böll, Victoria Metaxa   +2 more
exaly  

Selectively Engaging β-Arrestins at the Angiotensin II Type 1 Receptor Reduces Blood Pressure and Increases Cardiac Performance

Journal of Pharmacology and Experimental Therapeutics, 2010
Jonathan D. Violin, S. Dewire, D. Yamashita, D. Rominger, L. Nguyen, Kevin Schiller, E. Whalen, M. Gowen, M. Lark   +8 more
semanticscholar   +1 more source

Breast Cancer Statistics, 2022

Ca-A Cancer Journal for Clinicians, 2022
Hyuna Sung, Kimberly D Miller, Rebecca L Siegel   +2 more
exaly  

Current treatment and recent progress in gastric cancer

Ca-A Cancer Journal for Clinicians, 2021
Smita S Joshi, Brian D Badgwell
exaly  

[Angiotensin II type 1 and type 2 receptor].

Nihon rinsho. Japanese journal of clinical medicine, 2009
The octapeptide angiotensin II (AngII) plays a homeostatic role in the regulation of blood pressure and water and electrolyte balance, and contributes to the progression of cardiovascular remodeling. AngII activates AngII type 1 (AT1) receptor and type 2 (AT2) receptor, both of which belong to the seven-transmembrane, G protein-coupled receptor family.
Hiroshi, Akazawa, Issei, Komuro
openaire   +1 more source

Oxidized LDL (oxLDL) activates the angiotensin II type 1 receptor by binding to the lectin‐like oxLDL receptor

The FASEB Journal, 2015
Koichi Yamamoto, A. Kakino, H. Takeshita, Norihiro Hayashi, Lei Li, A. Nakano, Hiroko Hanasaki-Yamamoto, Y. Fujita, Yuki Imaizumi, Serina Toyama-Yokoyama, Chikako Nakama, Tatsuo Kawai, M. Takeda, Kazuhiro Hongyo, R. Oguro, Y. Maekawa, N. Itoh, Y. Takami, Miyuki Onishi, Y. Takeya, K. Sugimoto, K. Kamide, H. Nakagami, M. Ohishi, T. Kurtz, T. Sawamura, H. Rakugi   +26 more
semanticscholar   +1 more source

Impact of angiotensin I converting enzyme inhibitors and angiotensin II type 1 receptor blockers on survival in patients with advanced non-small-cell lung cancer undergoing first-line platinum-based chemotherapy

Journal of Cancer Research and Clinical Oncology, 2009
S. Wilop, S. Hobe, M. Crysandt, Albert Esser, R. Osieka, E. Jost   +5 more
semanticscholar   +1 more source

A review of cancer immunotherapy toxicity

Ca-A Cancer Journal for Clinicians, 2020
Lucy Boyce Kennedy
exaly